** Shares of specialty pharma firm Scienture Holdings SCNX.O rise ~60% to $3.55 premarket
** SCNX says it is launching Rezenopy nasal spray 10mg, an opioid overdose emergency drug, through a collaboration with Kindeva Drug Delivery L.P.
** Kindeva will manufacture and supply Rezenopy, while SCNX will own the marketing application and be responsible for sales, marketing, and distribution in the U.S.
** Rezenopy is the most potent version of naloxone HCl available in the market, co says
** SCNX gained 81.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。